Medication info

Traglime Duo Tablet 2.5/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Mothers Pharmaceuticals Co., Ltd.
Appearance
Bright orange, double convex, oval film-coated tablet
Packaging
60 tablets/PTP - 60 tablets/PTP [10 tablets/PTP packaging x 6 packs]
Approval status
Expired

MFDS item code 201908712 · Approved 2019.12.31

This product's status changed to Expired on 2024.12.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, dose increases should be gradual. Patients not currently treated with metformin: The starting dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. Patients who do not achieve adequate glycemic control with metformin monotherapy: The starting dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). Patients switching from combination therapy with linagliptin and metformin: Start at the current doses of linagliptin and metformin. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The starting dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The starting dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment: This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment: This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Mothers Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty controlling blood sugar
View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar levels in adult patients with type 2 diabetes. It is administered when there has been no previous treatment with diabetes medications or when blood sugar control is insufficient with monotherapy. It can also be used when sufficient blood sugar control is not achieved with metformin monotherapy. Additionally, this medication is co-administered when switching from the combination of linagliptin and metformin, or when blood sugar is not controlled with maximum doses of metformin and sulfonylureas, or insulin. This medication is also used to improve blood sugar control when empagliflozin and metformin combination therapy is ineffective. Therefore, it is effectively used for blood sugar control in type 2 diabetes requiring combination therapy.

How to take

Adult dose

The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, dose increases should be gradual. Patients not currently treated with metformin: The starting dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. Patients who do not achieve adequate glycemic control with metformin monotherapy: The starting dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). Patients switching from combination therapy with linagliptin and metformin: Start at the current doses of linagliptin and metformin. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The starting dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The starting dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment: This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment: This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication can cause serious metabolic complications known as lactic acidosis, so it should not be administered to certain patients. For example, patients who are allergic to any component of this medication, type 1 diabetes patients, patients with severe renal impairment, acute heart disease, or liver dysfunction may be at risk if they use this medication. Moreover, it is recommended that pregnant or lactating women avoid taking this medication. When using this medication, care should be taken for symptoms of hypoglycemia, especially when taken in combination with other blood glucose-lowering medications as the risk of hypoglycemia may increase. Due to the risk of lactic acidosis, this medication should be discontinued immediately in situations involving dehydration, severe infections, or acute deterioration of kidney function. Patients with reduced renal function should have regular kidney function tests, and this medication should not be taken if kidney function falls below a certain level. Patients with weakened heart function should also use this medication with caution, and if symptoms of acute pancreatitis or skin disorders like bullous pemphigoid arise, immediate consultation with a doctor is necessary. This medication can lower vitamin B12 levels, so patients on long-term therapy should periodically monitor for vitamin B12 deficiency. Additionally, this medication may interact with other medications, so if other medications are being taken, consultation with a physician or pharmacist is essential. Women who are pregnant or planning to become pregnant are advised to receive insulin therapy instead of this medication for blood glucose control. This medication is not to be used in children under the age of 10, and safety and efficacy have not been established for adolescents aged 10 to 17. Elderly patients should be closely monitored for renal function since renal impairment is common, and typically, the maximum dose is not used. In case of overdose, the risk of lactic acidosis exists, requiring immediate medical treatment, with hemodialysis being the most effective treatment method. This medication should be stored out of reach of children, protected from moisture, and should not be transferred to other containers.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 125 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and debilitating arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • diarrhea
  • hypoglycemia
  • stomatitis
  • fever
  • facial edema
  • fatigue
  • pneumonia
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • meniscus injury
  • foot fracture
  • hand fracture
  • pneumoconiosis
  • laceration
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • polyuria
  • proteinuria
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • hearing loss
  • erectile dysfunction
  • goiter
  • kidney transplant failure
  • anemia
  • dizziness
  • sensory impairment
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • pneumonia
  • rhinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • upper abdominal pain
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • hypercholesterolemia
  • inadequate control of diabetes
  • malnutrition
  • hyponatremia
  • dehydration
  • headache
  • drowsiness
  • asthenia
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • male pattern baldness
  • hyperhidrosis
  • dermatitis
  • anxiety
  • confusion state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius to preserve the effectiveness and safety of the medication for a long time.

Appearance and packaging

Appearance

Bright orange, double convex, oval film-coated tablet

Package unit

60 tablets/PTP - 60 tablets/PTP [10 tablets/PTP packaging x 6 packs]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.